Lifesci Capital Weighs in on CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Perspective Therapeutics in a report released on Thursday, March 27th. Lifesci Capital analyst D. Kennedy forecasts that the company will post earnings per share of ($0.28) for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.10) EPS.

A number of other research firms also recently commented on CATX. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Stock Down 8.0 %

NYSE:CATX opened at $1.96 on Monday. The firm’s 50 day moving average is $2.88 and its two-hundred day moving average is $6.10. Perspective Therapeutics has a fifty-two week low of $1.90 and a fifty-two week high of $19.05.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics during the 4th quarter valued at approximately $33,000. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at approximately $34,000. National Bank of Canada FI grew its position in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in shares of Perspective Therapeutics in the fourth quarter worth $51,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Juan Graham purchased 33,333 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III acquired 38,145 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was purchased at an average cost of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now owns 108,982 shares in the company, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock worth $256,344 in the last 90 days. 3.52% of the stock is owned by company insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.